Suggested slug: ovagen-research-guide

Status: Locked citation-verified draft. Not published. Not for WordPress.

Research-use-only framing. This page describes a short peptide bioregulator sold as a laboratory research material. It is not medical advice. Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

One-sentence identity. Ovagen is a synthetic tripeptide printed in opened Khavinson-group full texts as Glu-Asp-Leu (EDL) (also coded T-35 on one opened kidney-culture abstract), positioned as a short “peptide bioregulator”; opened experimental work is almost entirely renal-cell / rat-kidney and in-silico docking, English-language independently replicated evidence is limited, ClinicalTrials.gov returned 0 studies for the trade name, and it is not veterinary ovine-FSH Ovagen, not Livagen, not Epitalon/Epithalon, not Pinealon, not Chonluten, not Vesugen, and not hCG/FSH/LH.

–-

SRP product and index pages do not print a sequence, CAS, UNII, molecular formula, or a public COA. The sequence below is taken only from opened primary/review papers that print the trade name Ovagen next to Glu-Asp-Leu / EDL, plus the opened PubChem record for glutamyl-aspartyl-leucine. PubChem does not list the trade name Ovagen as a title or synonym.

What this is chemically, from opened pages. Two opened Khavinson-group full texts print Ovagen (EDL) / EDL, Ovagen as the unmodified tripeptide Glu-Asp-Leu. One opened kidney-culture abstract prints the same three letters as T-35 (EDL). PubChem CID 444128 and ChEBI 137252 are the matching L-Glu–L-Asp–L-Leu structure (C15H25N3O8; InChIKey JVSBYEDSSRZQGV-GUBZILKMSA-N). Those registry records do not print the marketplace name Ovagen. No CAS RN was present on the opened PubChem CID.

What this is not, chemically.

• Not veterinary Ovagen, an ovine FSH / superovulation product (opened example: McNatty et al. 1989, PMID 16031503, “goats treated with Ovagen and Folltropin”). The entire PubMed Ovagen hit list opened this session belongs to that collision class.
• Not Livagen (Lys-Glu-Asp-Ala / KEDA). Same 2022 table, different row.
• Not Epitalon / Epithalon (Ala-Glu-Asp-Gly / AEDG).
• Not Pinealon (Glu-Asp-Arg / EDR).
• Not Chonluten (Glu-Asp-Gly / EDG).
• Not Vesugen (Lys-Glu-Asp / KED).
• Not hCG, FSH, or LH, and not a gonadotropin receptor agonist on any opened page.
• Not shown on any opened page to be compositionally identical to an SRP 20 mg lyophilized research vial. SRP itself tells the buyer to “verify sequence, salt form, and assay.”

Not printed on SRP pages and therefore not claimed as SRP-verified: sequence, CAS, UNII, formula, T-35 code, or purity numbers. The product page does not print a public COA.

Tissue-association honesty. The trade name and the SRP product tag Reproductive Research / “reproductive-tissue models” create a marketplace expectation of ovarian targeting. Opened Khavinson full texts do not print Ovagen as an ovarian cytomedin. PMID 35887081 Table 2 labels Ovagen (EDL) Nephroprotector / Hepatoprotector. PMID 34834147 Table 5 lists “EDL, Ovagen” as “regulation of renal cells’ function, hepatoprotection, DNA binding.” Opened primary experiments that actually apply EDL / T-35 are kidney-cell and rat-kidney designs. A dedicated ovarian or fertility paper naming Ovagen/EDL was not located. Do not treat the name, the SRP reproductive tag, or veterinary FSH literature as evidence of ovarian pharmacology.

–-

Ovagen (this page) is the tripeptide Glu-Asp-Leu (EDL) on the opened 2021 and 2022 Khavinson full texts, and T-35 (EDL) on the opened 2014 kidney-culture abstract. It is one name inside the Khavinson / cytomedin-style short-peptide bioregulator catalog. That catalog is a research-network taxonomy, not a receptor-class assignment.

–-

Product URL: http://simpleresearchpeptides.com/product/ovagen-20-mg/

Fetched page title: “Ovagen 20 mg Research Peptide Vial”. Breadcrumb/tags: Peptide Bioregulators, Reproductive Research, Research Peptides. Body: “one 20 mg research vial; verify sequence, salt form, and assay. Organized for reproductive-tissue models, short-peptide signaling, and peptide-bioregulator characterization. For laboratory research use only.” Research material: Ovagen. Listed strength and format: 20 mg. Research category: Peptide Bioregulators. Disclaimer: “For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.” Reviews (0). Sequence, CAS, UNII, formula, and a public COA were not printed. A dollar price was not captured on the fetched page (the page printed “Sale!” only).

Index card on http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/: Longevity → “Ovagen 20 mg”; Evidence profile (not a dedicated long-form guide). Evidence tag: Sparse/limited evidence. Overview text on that index: marketed as a short peptide bioregulator associated with liver and gastrointestinal research in some catalogs; definitions and naming may vary; claims generally refer to tissue-specific gene-regulatory effects, but a well-replicated receptor-level mechanism is not established; independent, well-controlled human studies are sparse; verify sequence, nomenclature, and the intended tissue association before matching the product with publications. Last editorial review printed on that index: August 2026.

Dedicated guide URL http://simpleresearchpeptides.com/research-compound-directory/ovagen-research-guide/ returned HTTP 404.

Educational information only. No human dosing, reconstitution, or administration protocol appears on this page.

–-

Ovagen, on opened Khavinson-group pages, is the synthetic tripeptide Glu-Asp-Leu (EDL). The indexed experimental footprint that actually applies that sequence is small and concentrated in one research network:

1. Renal epithelial cell-culture aging. T-35 (EDL) was applied to primary kidney-cell cultures; the opened abstract reports MMP-14 as the T-35 target, while a related polypeptide complex and T-31 (AED) were the agents tied to cell-renewal markers (PMID 24958378). A Russian-language companion (PMID 25946838) reports AED and EDL increasing proliferation and lowering p16 / p21 / p53 while raising SIRT-6 in young and aged renal cultures, plus a docking model to d(ATATATATAT)2.
2. Rat kidney-injury / aging models. EDL is named in cisplatin acute-renal-failure (PMID 26515176), gentamicin and ischemia/reperfusion injury (PMID 28744634), and old-rat kidney function (PMID 30607912) papers from the Zamorskii / Khavinson group.
3. In-silico DNA and transporter docking. EDL is docked to a ctcc DNA motif alongside AEDL (PMID 27909961). Ovagen (EDL) is assigned LAT1 ICM-score −28.27 on a 27-peptide table (PMID 35887081). These are computational scores, not measured uptake or promoter occupancy.

The trade name Ovagen itself is absent from PubMed title/abstract indexing (Ovagen AND Khavinson = 0). It appears in opened full-text tables, not in the PubMed-visible abstracts of the kidney papers. A PubMed search for Ovagen alone returns veterinary FSH / superovulation records and must not be mined as peptide evidence.

No opened Western independent replication, no opened human pharmacokinetic study, and no ClinicalTrials.gov record were located.

–-

Observed in opened EDL-named or Ovagen-named records

• Kidney-culture marker shift (T-35 / EDL). In aging primary kidney-cell cultures, “gelatinase MMP-14 is the target of T-35 peptide,” while a calf-kidney polypeptide complex and T-31 (AED) “activate cell renewal processes” (Ki-67, p53, IL-8 also on the panel) (Khavinson et al. 2014, PMID 24958378). This is an ex vivo culture abstract, not a clinical trial.
• Renal-culture senescence markers (AED and EDL). Russian-language *Adv Gerontol* paper: AED and EDL “increase cell proliferation, decreasing expression of marker of aging p16, p21, p53 and increasing expression of SIRT-6 in young and aged renal cell culture.” Both peptides are modeled as forming energetically favorable complexes with d(ATATATATAT)2 in the DNA minor groove (Khavinson et al. 2014, PMID 25946838). MeSH/chemicals on that record include glutamyl-aspartyl-leucine.
• Rat nephroprotection language (EDL peptide). In gentamicin nephropathy and ischemia/reperfusion, “EDL peptide produced a nephroprotective effect” described as prevention of oliguria and retention azotemia, decreased proteinuria and sodium excretion, preservation of antioxidant-enzyme activity, suppression of lipid peroxidation, and “normalization of energy supply to kidneys cells” (Zamorskii et al. 2017, PMID 28744634). In cisplatin acute renal failure, EDL (with a kidney polypeptide complex and AEDG) “normalized diuresis, creatinine concentration… glomerular filtration rate,” and the abstract states “EDL peptide produced was potent nephroprotective effect” (Zamorskii et al. 2015, PMID 26515176). In old rats, EDL (with PKC, AED, AEDG) increased diuresis and distal sodium transport; the authors conclude these peptides “may be considered as nephroprotective agents in kidney aging” (Zamorskii et al. 2018, PMID 30607912). These are Khavinson-network rodent abstracts, not independent replications.
• DNA-motif docking (EDL, not the trade name). “Peptides AEDL and EDL [bind] to ctcc sequence” among 19 docked short peptides (Khavinson, Lin’kova, Tarnovskaya 2016, PMID 27909961). No wet-lab footprint, EMSA, or ChIP is on the opened abstract.
• LAT1 docking table (trade name printed). Ovagen (EDL) ICM-score −28.27, labeled Nephroprotector / Hepatoprotector, on a computed LAT1-binding table of 27 ultrashort peptides (Khavinson et al. 2022, PMID 35887081, Table 2). The paper is a review plus docking. It does not report a measured PEPT/LAT flux for EDL.

Review-table claims that outrun the opened primary set

• PMID 34834147 Table 5 lists “EDL, Ovagen” as “regulation of renal cells’ function, hepatoprotection, DNA binding” and points at reference [74], which is the kidney-culture paper PMID 24958378. A primary liver-injury experiment that names Ovagen or EDL was not opened this session. Treat “hepatoprotector” as author-table language, not as a verified hepatic trial.

Not shown in a paper opened here

• A registered ClinicalTrials.gov or WHO-ICTRP trial (NCT for Ovagen: none).
• A peer-reviewed randomized, placebo-controlled human efficacy trial.
• Human pharmacokinetics (half-life, bioavailability, tissue distribution) for synthetic EDL.
• A modern receptor-panel Ki table, crystal structure of EDL bound to a human target, or a PEPT1/PEPT2 uptake assay that actually used Ovagen/EDL as the substrate.
• An opened ovarian, oocyte, granulosa, or fertility experiment that names Ovagen or EDL.
• Independent Western-laboratory replication of the kidney-culture or rat-injury findings.
• FDA, EMA, or NCATS approval / UNII.

Do not treat as Ovagen evidence: veterinary Ovagen / ovine FSH / Folltropin papers; hCG, FSH, or LH clinical literature; Livagen / KEDA hepatocyte papers; Epitalon telomerase papers; Pinealon / EDR neuro papers; Chonluten / EDG respiratory papers; Vesugen / KED vascular papers; HIV-1 protease / PDB 1a30 ligand papers; vendor blogs that assign an invented CAS.

–-

NCBI E-utilities db=pubmed&term=Ovagen returned count 34 on 16 August 2026. Opened titles in that set are veterinary FSH / superovulation / embryo-transfer records. None were used as EDL evidence. Ovagen AND Khavinson returned 0. Khavinson AND (EDL OR Ovagen OR "Glu-Asp-Leu" OR T-35) returned 10 PMIDs; only records whose opened abstract or full text actually discusses EDL / T-35 / Ovagen are summarized below.

Khavinson, Linkova, Kozhevnikova, Dyatlova, Petukhov, 2022, *Int J Mol Sci* (PMID 35887081; PMC9323678; DOI 10.3390/ijms23147733). Transport of biologically active ultrashort peptides using POT and LAT carriers. 23(14):7733. Opened full-text XML Table 2 prints Ovagen (EDL), ICM-score −28.27, biological-activity label “Nephroprotector [165] Hepatoprotector [166].” Same table prints Livagen (KEDA), Epitalon (AEDG), Pinealon (EDR), Chonluten (EDG), Vesugen (KED) as separate rows. Docking / review, not a wet-lab transport assay.

Khavinson, Popovich, Linkova, Mironova, Ilina, 2021, *Molecules* (PMID 34834147; PMC8619776; DOI 10.3390/molecules26227053). Peptide regulation of gene expression: a systematic review. 26(22):7053. Opened full-text XML Table 5 row 4: “EDL, Ovagen” — “regulation of renal cells’ function, hepatoprotection, DNA binding” — reference [74] = PMID 24958378. Review table, not a new experiment.

Khavinson, Lin’kova, Tarnovskaya, 2016, *Bull Exp Biol Med* (PMID 27909961; DOI 10.1007/s10517-016-3596-7). Short peptides regulate gene expression. 162(2):288–292. Opened abstract: spatial models for 19 short peptides; “peptides AEDL and EDL to ctcc sequence.” Does not print the trade name Ovagen on the opened abstract.

Khavinson, Lin’kova, Polyakova, Durnova, Nichik, Kvetnoi, 2014, *Bull Exp Biol Med* (PMID 24958378; DOI 10.1007/s10517-014-2540-y). Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. 157(2):261–264. Opened abstract: calf-kidney polypeptide complex, T-31 (AED), and T-35 (EDL) on Ki-67, p53, MMP-14, IL-8 in primary kidney cultures during aging. Complex and T-31 “activate cell renewal”; “gelatinase MMP-14 is the target of T-35 peptide.” Does not print the trade name Ovagen on the opened abstract.

Khavinson et al., 2014, *Adv Gerontol* (PMID 25946838). [Tripeptides slow down aging process in renal cell culture]. 27(4):651–656. Russian. Opened abstract: peptides AED and EDL increase proliferation, decrease p16 / p21 / p53, increase SIRT-6 in young and aged renal cultures; docking to d(ATATATATAT)2. Chemicals on the Europe PMC core record include glutamyl-aspartyl-leucine. Does not print Ovagen on the opened abstract.

Zamorskii, Shchudrova, Lin’kova, Nichik, Khavinson, 2015, *Bull Exp Biol Med* (PMID 26515176; DOI 10.1007/s10517-015-3062-y). Peptides restore functional state of the kidneys during cisplatin-induced acute renal failure. 159(6):736–739. Opened abstract: kidney polypeptide complex plus AED, EDL, and AEDG in cisplatin ARF rats; EDL described as producing a potent nephroprotective effect on diuresis, creatinine, GFR, and electrolyte endpoints. Not a human trial. Does not print Ovagen on the opened abstract.

Zamorskii, Shchudrova, Lin’kova, Nichik, Khavinson, 2017, *Bull Exp Biol Med* (PMID 28744634; DOI 10.1007/s10517-017-3811-1). Nephroprotective effect of EDL peptide at acute injury of kidneys of different genesis. 163(3):389–393. Opened abstract: gentamicin nephropathy and ischemia/reperfusion in rats; oliguria / azotemia / proteinuria / antioxidant-enzyme / LPO language as above. Does not print Ovagen on the opened abstract.

Zamorskii, Shchudrova, Zeleniuk, Linkova, Nichik, Khavinson, 2018, *Adv Gerontol* (PMID 30607912). [The influence of peptides on the morphofunctional state of old rats kidneys.] 31(4):498–504. Russian. Opened abstract: PKC, AED, EDL, AEDG in old rats; diuresis and sodium-handling changes; authors propose nephroprotective use in kidney aging. Does not print Ovagen on the opened abstract.

• PMID 22808515 (tissue-specific differentiation): opened abstract names pancragen, bronchogen, vesugen — not EDL or Ovagen.
• PMID 28371610 (tobacco CLE/KNOX1/GRF): opened abstract names epitalon, bronchogen, vilon — not EDL or Ovagen.
• PMID 16031503 and the rest of the PubMed Ovagen FSH/superovulation set: veterinary ovine FSH.
• CT.gov Glu-Asp-Leu (35) and EDL peptide (8): opened first titles are diet, cold-water immersion, oncology antibody, HIV, HPV vaccine studies — amino-acid-string / acronym collisions.

–-

• Not an ovarian hormone and not a fertility drug. Opened primary papers do not print ovarian, oocyte, granulosa, or gonadotropin-receptor data for EDL. Do not analogize to hCG, FSH, LH, or kisspeptin.
• Not veterinary Ovagen (ovine FSH). That is a different substance used in livestock superovulation papers (PMID 16031503 and the PubMed Ovagen collision set).
• Not Livagen (KEDA), Epitalon/Epithalon (AEDG), Pinealon (EDR), Chonluten (EDG), or Vesugen (KED). Those sequences are separate rows on the opened 2022 LAT1 table.
• Not T-31 (AED / Cartalax). PMID 24958378 tests T-31 and T-35 side by side.
• Not an FDA-approved drug, INN, or NCATS substance. Opened Drugs@FDA, NCATS ovagen, and IUPHAR ligand searches were empty.
• Not a vial with a verified public sequence/COA on the SRP page. The listing tells the buyer to verify sequence, salt form, and assay.

–-

• Materials sold as Ovagen are for laboratory research use only. They are not for human or veterinary administration, compounding, or fertility protocols.
• Identify the vial by sequence (Glu-Asp-Leu / EDL), not by the trade name alone. The same marketplace name is used for an unrelated ovine-FSH product in the veterinary literature.
• Confirm salt form, net peptide content, and chromatographic purity on a batch COA. SRP’s fetched product page does not print those numbers.
• Do not assume ovarian-cell activity from the name or from the SRP “Reproductive Research” tag. Opened Khavinson experiments that apply EDL are kidney models.
• This page does not provide reconstitution, solvent, concentration, or dosing instructions.
• Handle lyophilized peptides with standard laboratory controls (identity assay, endotoxin if the design requires it, documented storage). Those are general RUO practices, not a protocol for this compound.

–-

Ovagen 20 mg — http://simpleresearchpeptides.com/product/ovagen-20-mg/ Opened page title: “Ovagen 20 mg Research Peptide Vial”. Breadcrumb/tags: Peptide Bioregulators, Reproductive Research, Research Peptides. Lead line: “one 20 mg research vial; verify sequence, salt form, and assay. Organized for reproductive-tissue models, short-peptide signaling, and peptide-bioregulator characterization. For laboratory research use only.” Description bullets: research material Ovagen; listed strength and format 20 mg; research category Peptide Bioregulators. Footer: “For laboratory research only. Not for human or animal use, consumption, administration, diagnosis, treatment, or therapeutic application.” Sequence, CAS, UNII, molecular formula, and a public COA were not printed on the fetched page.

Index entry — http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/ Listing: “Ovagen 20 mg” under Longevity; “Evidence profile.” Body: “Ovagen is marketed as a short peptide bioregulator associated with liver and gastrointestinal research in some catalogs. Definitions and naming may vary.” Evidence tag: Sparse/limited evidence. Research-quality note: “Verify sequence, nomenclature, and the intended tissue association before matching the product with publications.”

–-

Sources actually opened for this draft:

1. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. *Int J Mol Sci.* 2022;23(14):7733. PMID 35887081. DOI 10.3390/ijms23147733. PMC 9323678. Full-text XML opened; Table 2 prints Ovagen (EDL).
2. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. *Molecules.* 2021;26(22):7053. PMID 34834147. DOI 10.3390/molecules26227053. PMC 8619776. Full-text XML opened; Table 5 prints EDL, Ovagen.
3. Khavinson VKh, Lin’kova NS, Polyakova VO, Durnova AO, Nichik TE, Kvetnoi IM. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging. *Bull Exp Biol Med.* 2014;157(2):261–264. PMID 24958378. DOI 10.1007/s10517-014-2540-y. T-35 (EDL); abstract opened.
4. Khavinson VKh, Tarnovskaia SI, Lin’kova NS, et al. [Tripeptides slow down aging process in renal cell culture]. *Adv Gerontol.* 2014;27(4):651–656. PMID 25946838. AED and EDL; abstract opened.
5. Zamorskii II, Shchudrova TS, Lin’kova NS, Nichik TE, Khavinson VKh. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. *Bull Exp Biol Med.* 2015;159(6):736–739. PMID 26515176. DOI 10.1007/s10517-015-3062-y. EDL named; abstract opened.
6. Zamorskii II, Shchudrova TS, Lin’kova NS, Nichik TE, Khavinson VK. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. *Bull Exp Biol Med.* 2017;163(3):389–393. PMID 28744634. DOI 10.1007/s10517-017-3811-1. EDL named; abstract opened.
7. Zamorskii II, Shchudrova TS, Zeleniuk VG, Linkova NS, Nichik TE, Khavinson VK. [The influence of peptides on the morphofunctional state of old rats kidneys.] *Adv Gerontol.* 2018;31(4):498–504. PMID 30607912. EDL named; abstract opened.
8. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. *Bull Exp Biol Med.* 2016;162(2):288–292. PMID 27909961. DOI 10.1007/s10517-016-3596-7. EDL → ctcc docking; abstract opened.
9. Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. *Bull Exp Biol Med.* 2012;153(1):148–151. PMID 22808515. DOI 10.1007/s10517-012-1664-1. Opened for distinction — does not name EDL/Ovagen.
10. Fedoreyeva LI, Dilovarova TA, Ashapkin VV, et al. Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum. *Biochemistry (Mosc).* 2017;82(4):521–528. PMID 28371610. DOI 10.1134/s0006297917040149. Opened for distinction — epitalon/bronchogen/vilon only.
11. McNatty KP, Hudson NL, Ball K, Mason A, Simmons MH. Superovulation and embryo recovery in goats treated with Ovagen and Folltropin. *N Z Vet J.* 1989;37(1):27–29. PMID 16031503. DOI 10.1080/00480169.1989.35543. Veterinary ovine-FSH name collision.
12. PubChem CID 444128 (glutamyl-aspartyl-leucine / Glu-Asp-Leu; C15H25N3O8; InChIKey JVSBYEDSSRZQGV-GUBZILKMSA-N). https://pubchem.ncbi.nlm.nih.gov/compound/444128 and PUG REST (opened 16 August 2026). No Ovagen synonym; no CAS RN.
13. ChEBI 137252 (Glu-Asp-Leu). https://www.ebi.ac.uk/chebi/CHEBI:137252 and public compound REST (opened 16 August 2026). No Ovagen name.
14. ClinicalTrials.gov API v2 query ovagen — 0 studies; Glu-Asp-Leu and EDL peptide logged as collisions (opened 16 August 2026).
15. NCATS Inxight substances search ovagen — total 0 (opened 16 August 2026).
16. openFDA Drugs@FDA ovagen — no matches (opened 16 August 2026).
17. IUPHAR/BPS ligand search API — no ligands for Ovagen or Glu-Asp-Leu (opened 16 August 2026).
18. NCBI E-utilities PubMed Ovagen (34, collision set), Ovagen AND Khavinson (0), Khavinson AND (EDL OR Ovagen OR "Glu-Asp-Leu" OR T-35) (10) (opened 16 August 2026).
19. SRP product page (opened 16 August 2026): http://simpleresearchpeptides.com/product/ovagen-20-mg/
20. SRP compound index (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/compound-research-guides/
21. SRP dedicated guide URL — HTTP 404 (opened 16 August 2026): http://simpleresearchpeptides.com/research-compound-directory/ovagen-research-guide/
22. SRP homepage (opened 16 August 2026): http://simpleresearchpeptides.com/

–-